Cargando…

Efgartigimod alfa for the treatment of primary immune thrombocytopenia

Primary immune thrombocytopenia (ITP) is an acquired autoimmune disorder characterized by isolated thrombocytopenia. Most patients with ITP have antiplatelet antibodies of the immunoglobulin G (IgG) subtype which through interaction with platelet and megakaryocyte glycoproteins result in increased p...

Descripción completa

Detalles Bibliográficos
Autor principal:	Broome, Catherine
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	SAGE Publications 2023
Materias:	Review
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10176552/ https://www.ncbi.nlm.nih.gov/pubmed/37188068 http://dx.doi.org/10.1177/20406207231172831

Ejemplares similares

S302: LONG-TERM SAFETY AND EFFICACY OF EFGARTIGIMOD IN PATIENTS WITH PRIMARY IMMUNE THROMBOCYTOPENIA: INTERIM RESULTS OF THE ADVANCE+ STUDY
por: Carpenedo, Monica, et al.
Publicado: (2023)

Efgartigimod Alfa in Generalised Myasthenia Gravis: A Profile of Its Use
por: Heo, Young-A
Publicado: (2023)

Correction to: Efgartigimod Alfa in Generalised Myasthenia Gravis: A Profile of Its Use
por: Heo, Young-A
Publicado: (2023)

Phase 2 study of efgartigimod, a novel FcRn antagonist, in adult patients with primary immune thrombocytopenia
por: Newland, Adrian C., et al.
Publicado: (2019)

Efgartigimod: First Approval
por: Heo, Young-A
Publicado: (2022)

Correction to: Efgartigimod: First Approval
por: Heo, Young-A
Publicado: (2022)

A Critical Examination for the Pricing of Eculizumab and Efgartigimod in Myasthenia Gravis
por: Langley, Paul C.
Publicado: (2021)

PB2305: EFGARTIGIMOD: CLINICAL DEVELOPMENT OF A NOVEL FCRN ANTAGONIST IN THE TREATMENT OF AUTOIMMUNE DISEASES
por: Knoebl, P., et al.
Publicado: (2022)

Roles of FcRn in Antigen-Presenting Cells during Autoimmunity and a Clinical Evaluation of Efgartigimod as an FcRn Blocker
por: Zhou, Yihan, et al.
Publicado: (2023)

Recombinant follitropin alfa/lutropin alfa in fertility treatment
por: Gibreel, Ahmed, et al.
Publicado: (2010)

Current Management of Primary Immune Thrombocytopenia
por: Provan, Drew, et al.
Publicado: (2015)

Avatrombopag for the treatment of immune thrombocytopenia and thrombocytopenia of chronic liver disease
por: Cheloff, Abraham Z, et al.
Publicado: (2019)

Immune Thrombocytopenia in Antiphospholipid Syndrome: Is It Primary or Secondary?
por: Tomasello, Riccardo, et al.
Publicado: (2021)

Switching thrombopoietin receptor agonist treatments in patients with primary immune thrombocytopenia
por: González-Porras, José R., et al.
Publicado: (2019)

Treatments for Primary Immune Thrombocytopenia: A Review
por: Samson, Margot, et al.
Publicado: (2019)

Primary immune thrombocytopenia: a ‘diagnosis of exclusion’?
por: Visweshwar, Nathan, et al.
Publicado: (2022)

Advances in Diagnosis and Treatments for Immune Thrombocytopenia
por: Nomura, Shosaku
Publicado: (2016)

How we treat primary immune thrombocytopenia in adults
por: Liu, Xin-guang, et al.
Publicado: (2023)

Scoping Review on Epigenetic Mechanisms in Primary Immune Thrombocytopenia
por: Tan, Jian Hong, et al.
Publicado: (2023)

Conestat alfa for the treatment of angioedema attacks
por: Davis, Benjamin, et al.
Publicado: (2011)

Stabilization of Keratinocyte Monolayer Integrity in the Presence of Anti-Desmoglein-3 Antibodies through FcRn Blockade with Efgartigimod: Novel Treatment Paradigm for Pemphigus?
por: Zakrzewicz, Anna, et al.
Publicado: (2022)

Treatment of drug-induced immune thrombocytopenias
por: Marini, Irene, et al.
Publicado: (2022)

Primary Immune Thrombocytopenia: Novel Insights into Pathophysiology and Disease Management
por: Singh, Anurag, et al.
Publicado: (2021)

Recent advances in the mechanisms and treatment of immune thrombocytopenia
por: Provan, Drew, et al.
Publicado: (2022)

Immune Thrombocytopenia: Recent Advances in Pathogenesis and Treatments
por: Audia, Sylvain, et al.
Publicado: (2021)

Safety and efficacy of classical complement pathway inhibition with sutimlimab in chronic immune thrombocytopenia
por: Broome, Catherine M., et al.
Publicado: (2022)

Biomarkers for immune thrombocytopenia
por: Yu, Lingjia, et al.
Publicado: (2015)

Immunomodulatory and immunosuppressive drug protocols in the treatment of canine primary immune thrombocytopenia, a scoping review
por: Kristiansen, Peter Spanner, et al.
Publicado: (2021)

Practical aspects of treatment with drotrecogin alfa (activated)
por: Camporota, Luigi, et al.
Publicado: (2007)

Clonal hematopoiesis in primary immune thrombocytopenia
por: Wang, Yanming, et al.
Publicado: (2022)

Romiplostim in children with newly diagnosed or persistent primary immune thrombocytopenia
por: Grainger, John D., et al.
Publicado: (2021)

Recent advances in treatments of adult immune thrombocytopenia
por: Kim, Dae Sik
Publicado: (2022)

Evolving treatment modalities for immune thrombocytopenia in adults
por: Khadka, Sushmita, et al.
Publicado: (2021)

Changes in bone marrow morphology in adults receiving romiplostim for the treatment of thrombocytopenia associated with primary immune thrombocytopenia
por: Janssens, Ann, et al.
Publicado: (2016)

Anti-RhD immunoglobulin in the treatment of immune thrombocytopenia
por: Cheung, Eric, et al.
Publicado: (2009)

Romiplostim as a treatment for immune thrombocytopenia: a review
por: Chalmers, Sarah, et al.
Publicado: (2015)

Spotlight on eltrombopag in the treatment of children with chronic immune thrombocytopenia
por: Lambert, Michele P
Publicado: (2016)

Sequential Use of Efgartigimod and Romiplostim Restored Platelet Response in Two Multi-Refractory Thrombocytopenic Patients, Previously Treated with Thrombopoietin Receptor Agonists
por: Carpenedo, Monica, et al.
Publicado: (2023)

T cell immune abnormalities in immune thrombocytopenia
por: Ji, Xuebin, et al.
Publicado: (2014)

Agalsidase alfa (Replagal(™)) in the treatment of Anderson-Fabry disease
por: Pastores, Gregory M
Publicado: (2007)

Cannot write session to /tmp/vufind_sessions/sess_ht8rpgnpknop23iauc8f0t819u